JUPITER, Fla., Feb. 26, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed funding ...

Three patients living with hypertrophic cardiomyopathy have had their disease classification downgraded following a single ...

No biological system has been studied by more diverse approaches than the actin-based molecular motor myosin. Biophysics, biochemistry, physiology, classical genetics and molecular genetics have ...

Our skin and mucous membranes are protected by epithelial cells. This barrier tissue performs its function thanks to ...

Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replay will be ...

Cytokinetics has a strong cash runway but faces risks from its Royalty Pharma deal. Read more on what's ahead for this biotech and its assets.

View Full Profile. Learn about our Editorial Policies. A.S. Smith et al., “Myosin IIA interacts with the spectrin-actin membrane skeleton to control red blood cell membrane curvature and deformability ...

Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201SOUTH ...

Their work reveals a mechanism of interdependence of different forms of the cytoskeletal proteins actin and myosin, and their functions. The team also demonstrates the key role of gamma-actin in ...